Bladder Cancer

>

Latest News

Nadofaragene Firadenovec Delivers Durable Responses in Bladder Cancer
Nadofaragene Firadenovec Delivers Durable Responses in Bladder Cancer

April 11th 2024

Findings from a 3-year follow-up analysis found that nadofaragene firadenovec demonstrated durable, lasting results for patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer.

Study Shows Desire for Bladder-Sparing Treatments in High-Risk NMIBC
Study Shows Desire for Bladder-Sparing Treatments in High-Risk NMIBC

April 2nd 2024

Fitting ADC Therapy Into the Treatment Paradigm in Advanced Bladder Cancer
Fitting ADC Therapy Into the Treatment Paradigm in Advanced Bladder Cancer

March 14th 2024

Nivolumab With Chemotherapy Gains FDA Approval in Urothelial Cancer
Nivolumab With Chemotherapy Gains FDA Approval in Urothelial Cancer

March 7th 2024

Enfortumab Vedotin With Pembrolizumab Doubles Survival in Bladder Cancer
Enfortumab Vedotin With Pembrolizumab Doubles Survival in Bladder Cancer

March 6th 2024